GO
Loading...

Pfizer deal 'wounded,' not dead: Analyst

Monday, 19 May 2014 | 12:15 PM ET

AstraZeneca told Pfizer its final offer isn't good enough. Mark Schoenebaum, ISI Group biotech & pharma analyst, provides insight to the potential deal.